What are Emcure Pharma’s Plans for the Future?

    Emcure Pharmaceuticals was incorporated on April 16th, 1981. It is engaged in the development, manufacturing, and marketing of pharmaceutical products across the globe. The core strength of Emcure lies in producing in-house products that are commercialized through marketing infrastructure across geographies and relationships with multinational pharmaceutical companies. More about Emcure is described in the paragraphs below.

    Emcure Pharmaceuticals Ltd – Goals

    According to the MD, the company aims to become one of the top 5 pharma companies in the country in the next 5 to 7 years. It is also planning for some acquisitions to foster growth, as stated by a company official. As of 2021, the company was developing an mRNA vaccine for Covid-19 through Gennova Biopharmaceuticals, a subsidiary.

    While speaking to PTI, managing Director and Chief Executive officer Satish Mehta had said way back in 2021 that the company is currently one of the top 10 pharma firms in the country and that he would take the company among the top 5 for sure soon. He also said that this objective of taking the company to one among the top 5 is the main driving force for him.

    Emcure Pharmaceuticals Limited operates the key segments that include cardiovascular, HIV, gynecology, oncology, nephrology, vitamins and minerals, and anti-infectives said Mehta. When he was asked about increasing the manufacturing capacity, he stated that formulations and expansions of the manufacturing facilities could be carried out in two to three years in the drug or pharmaceutical industry. But more than manufacturing and expansion, what is required is marketing and creating demand for the Emcure Pharmaceuticals products. Once this occurs, manufacturing facilities can be increased.

    Emcure currently is in 70 markets across the globe, and one of the prime reasons the company has surged ahead in this industry is that it emphasizes a lot of research and development, as said by the MD. The company was looking forward to INR 40,000 crore initial public offerings and planned to file a draft red herring prospectus.

    Also Read: PharmEasy – Acquisition of Medlife and More

    Share this post at
    - Advertisement -spot_img
    Josie Patra
    Josie Patra is a veteran writer with 21 years of experience. She comes with multiple degrees in literature, computer applications, multimedia design, and management. She delves into a plethora of niches and offers expert guidance on finances, stock market, budgeting, marketing strategies, and such other domains. Josie has also authored books on management, productivity, and digital marketing strategies.

    Latest news

    Related news